The Three Pillars of a Sustainable GLP-1 Program

Dr. Nishu Uppal

Medical Director

Dr. Uppal is a practicing internal medicine physician and healthcare policy researcher trained at Brigham and Women's Hospital. He has published in leading journals including NEJM, JAMA, and Health Affairs, and holds an MD from Harvard Medical School and an MBA from Harvard Business School.

Most employers treating GLP-1 coverage as a procurement decision are asking the wrong question. The question isn't whether to cover GLP-1 medications. It's whether your coverage strategy is built to make them work.

A growing body of evidence says most aren't. A 2026 BMJ meta-analysis of GLP-1 withdrawal trials found that nearly all patients taking these medications primarily for weight loss regained the weight within one and a half to two years after stopping. Real-world adherence data is equally sobering: more than 50% of patients discontinue GLP-1 medications within 12 weeks, before meaningful weight loss has even occurred. More than 80% have stopped within two years.

These aren't outliers. They're the norm when GLP-1 coverage is structured around the medication itself rather than the conditions that determine whether the medication actually works.

A sustainable GLP-1 program is built on three pillars: lifestyle and behavioral support, medication adherence and clinical oversight, and consistent access. Each pillar is distinct and each is necessary. When any one of them is missing, the others will not compensate.

Why the Medication Alone Doesn't Sustain Results

It's worth being clear about what GLP-1 medications actually do before building any program around them. They are powerful tools that produce rapid, meaningful weight loss for many patients, often 10 to 20% of body weight in the first year. For a population that has struggled with obesity for years, sometimes decades, that early progress can be genuinely transformative.

But GLP-1 medications were never studied in isolation. The FDA approved tirzepatide and semaglutide based on Phase 3 clinical trials in which participants also followed structured nutrition and exercise programs. The medication worked in the context of coordinated behavioral support. Real-world GLP-1 programs are stripping that context out, and the results reflect it.

To illustrate the example, consider that GLP-1 medications are a tool, similar to SSRIs (antidepressants). Antidepressants reduce the neurochemical barriers to behavioral change; they don't replace the change itself. The same is true of GLP-1s. They quiet the constant preoccupation with food that many people with obesity carry. They reduce appetite and make early progress possible. But they don't address the underlying behavioral patterns, comorbid conditions, or emotional factors that made weight management so difficult in the first place. Without addressing those, the weight returns.

This is the coverage trap: employers pay for a medication that produces real results early, but watch those results evaporate when weight is regained. Not because the medication failed, but because the program around it wasn't built to sustain what the medication started.

Pillar 1: Lifestyle and Behavioral Support

The single most consistent predictor of long-term GLP-1 success is whether the patient has clinical behavioral support alongside the medication.

The behavioral challenges that derail GLP-1 adherence are clinical in nature and go beyond the need for wellness coaching or nutrition tips.

For example, research shows that 43% of adults with depression also have obesity, and the relationship runs in both directions. Depression reduces the motivation and self-regulation capacity that any weight management program requires. Emotional eating, the pattern of eating in response to negative emotion rather than hunger, is one of the primary ways depression drives weight gain, and GLP-1 medications reduce appetite without touching the emotional trigger underneath it.

Binge eating disorder, the most prevalent eating disorder overall, is another factor clinicians see regularly in patients pursuing GLP-1 treatment. In eating disorder care, underlying mental health factors must be addressed before focusing on weight loss. When they aren't, GLP-1 coverage can actually undermine the patient.

There's also a subtler dynamic that must not get lost. Many people who struggle with obesity have been told, explicitly and implicitly, that their weight is a character flaw. Years of that message leave a mark. Patients starting GLP-1 treatment often carry what researchers call weight bias internalization: the belief that their struggle reflects personal failure. When behavioral support is absent, that internalized shame can find new expressions as the medication changes the person's relationship with food.

What this means practically: a GLP-1 program without evidence-based behavioral health support, and without a mechanism for identifying and treating comorbid mental health conditions, is a program structured to fail in the long-term.

Effective behavioral support includes a dedicated relationship with a trained provider who can give ongoing accountability and motivational support, access to behavioral health resources for comorbid conditions, and nutrition guidance that helps patients build the dietary habits that will hold weight loss in place after the medication's effects stabilize.

Pillar 2: Medication Adherence and Clinical Oversight

Even when a patient is motivated and behaviorally supported, staying on a GLP-1 medication requires active clinical management. The adherence challenges are specific and predictable, and they go unresolved when there's no clinical oversight structure in place.

Side effects are the most immediate obstacle. Nausea and abdominal discomfort are common in the early weeks of GLP-1 treatment and cause roughly 30% of patients to discontinue within the first year. Patients who hit these side effects without a clinician they can reach in real time face a binary choice: manage through it alone or stop. Most stop.

Dose titration is a related problem that receives far less attention. Patients starting tirzepatide typically begin at 2.5 mg, a dose too low to produce meaningful weight loss. The therapeutic dose comes with uptitration, but the side effects that most commonly cause discontinuation occur during exactly that uptitration window. Patients who experience nausea while increasing their dose, without guidance on how to manage it, often conclude that the medication doesn't work for them and discontinue before reaching a dose that would have.

Beyond side effects, medication adherence depends on ongoing clinical monitoring of comorbid conditions. More than 80% of people with obesity have at least one comorbid chronic condition: MSK pain, sleep dysfunction, metabolic disease, or mental health conditions. These conditions aren't side effects of obesity. Rather, they are factors that make weight loss harder to achieve and sustain. A person with untreated chronic back pain cannot exercise at the level a weight management program requires. A person with depression cannot reliably maintain the dietary changes that reinforce what the medication starts. Treating these comorbidities in parallel with GLP-1 treatment isn't supplementary care. It's what makes the medication work.

A program built for adherence requires clinicians who monitor members through the uptitration process, respond to side effects in real time through digital access, and screen for and treat comorbid conditions throughout the care journey, not as a one-time intake step.

Pillar 3: Consistent, Stable Access

The third pillar is the one that employer benefits decisions most directly control, and the one most likely to be disrupted by plan changes, cost-share adjustments, or coverage policy shifts.

Here's the dynamic that makes access so consequential: for many patients, a GLP-1 medication is the first thing that has worked after years of trying and failing. The psychological experience of early success creates self-efficacy and begins to undo the narrative of personal failure that has accumulated over time. Behavioral health researchers call this interrupting the shame cycle.

When access is cut off, that process reverses sharply. The patient loses the progress they've made, but more than that, they lose the psychological foothold that progress had created. Returning to the starting point isn't neutral. For many patients, it confirms the narrative they were starting to overcome.

This is why coverage instability is, in some ways, worse than never offering coverage at all. Offering access that works, then removing it, creates harm in a clinical sense, not just a financial one.

Consistent access requires more than a coverage decision. It requires a defined cost-share structure that the employer and employee can sustain. It requires transparent pricing so that cost escalations don't force mid-year coverage changes.

New Direct-to-Employer GLP-1 programs are working to solve this problem. These programs are built directly with manufacturers such as Novo Nordisk and Lilly and operate as a carve out from the PBM. The models are built to have transparent pricing and employer-controlled cost shares to provide long-term financial viability.

What This Means for How You Employers Coverage

The employers getting the most from GLP-1 coverage aren't the ones who found the cheapest price per injection. They're the ones who recognized that the coverage decision and the program design decision are inseparable.

When GLP-1 coverage is embedded in a whole-person care program that provides behavioral support, clinical oversight, and comorbidity treatment alongside medication access, the outcomes are fundamentally different.

The ROI question that benefits leaders and CFOs are asking is legitimate. GLP-1 medications are expensive, the long-term cost projections are uncertain, and every dollar spent without a durable outcome is waste. But the answer to that question isn't to restrict access. It's to build the coverage program in a way that makes the medication's outcomes stick.

The three pillars aren't optional enhancements on top of a medication benefit. They're the architecture that determines whether the benefit produces a return.

Frequently Asked Questions

What makes a GLP-1 program sustainable for employers?

A sustainable GLP-1 program is built on three pillars: behavioral and lifestyle support to help employees make lasting changes, clinical oversight to manage side effects and comorbid conditions, and consistent access to medication that employees can count on. When any one of these is missing, discontinuation rates rise and weight regain becomes the likely outcome, eliminating the program's clinical and financial value.

Why do so many employees stop taking GLP-1 medications?

More than 50% of patients discontinue GLP-1 medications within 12 weeks, most often because of side effects, lack of clinical guidance during dose increases, or underlying conditions that haven't been addressed. GLP-1 medications ask a great deal of patients who may already be managing depression, chronic pain, or years of stigma around weight. Without a dedicated Health Coach and clinical oversight, the obstacles that cause discontinuation go unmanaged.

How do comorbidities affect GLP-1 outcomes?

More than 80% of people with obesity have at least one comorbid chronic condition, such as musculoskeletal pain, mental health conditions, or metabolic disease. These conditions directly undermine the behavioral changes that GLP-1 treatment requires. A person with untreated back pain cannot exercise; a person with depression cannot maintain dietary changes consistently. GLP-1 programs that treat weight in isolation, without addressing the conditions connected to it, produce lower adherence and faster weight regain.

What is the ROI on employer GLP-1 coverage?

The return on GLP-1 coverage comes primarily from preventing expensive downstream healthcare utilization, not from the weight number itself. Treating comorbid conditions like chronic back pain prevents the specialist visits, steroid injections, and procedures that accumulate when those conditions go unmanaged. Goodpath clients see a $2,292 PMPY reduction in total cost of care and a 30 to 51% reduction in short-term disability incidence, validated by an independent actuarial firm.

What are Direct-to-Employer GLP-1 Programs?

Employers receive direct pricing from Novo Nordisk and Lilly with no PBM rebates, full cost transparency, and employer-controlled cost share. Members access Wegovy (semaglutide) or Zepbound (tirzepatide) at 35% or more savings compared to PBM pricing.